A review of erlotinib and its clinical use

被引：85

作者：

Tang, PA

Tsao, MS

Moore, MJ

机构：

[1] Univ Toronto, Dept Pathol, Princess Margaret Hosp, Toronto, ON M5G 2M9, Canada

[2] Univ Toronto, Dept Med Oncol & Hematol, Princess Margaret Hosp, Toronto, ON M5G 2M9, Canada

来源：

EXPERT OPINION ON PHARMACOTHERAPY | 2006年 / 7卷 / 02期

关键词：

erlotinib; non-small cell lung cancer; pancreatic cancer; squamous cell cancer of the head and neck;

D O I：

10.1517/14656566.7.2.177

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Erlotinib is an orally available, reversible tyrosine kinase inhibitor of the epidermal growth factor receptor. Encouraging activity as a single agent and in corn bination with other targeted agents has been demonstrated in Phase 11 trials in many tumour types. Erlotinib has an established role in the treatment of advanced, refractory non-small cell lung cancer-based on a pivotal trial demonstrating a survival advantage over best supportive care. In a Phase III trial, the addition of erlotinib to gemcitabine improved survival in advanced pancreatic cancer. The toxicity profile of erlotinib includes diarrhoea and rash, with no haematological side effects. Predictive factors for response include the presence of a rash, epidermal growth factor receptor expression and mutation status. This article reviews the current clinical status of erlotinib.

引用

页码：177 / 193

页数：17

共 111 条

[21]

DRAGOVICH T, 2005, GASTR CANC S

[22] Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro [J].

Durkin, AJ ;

Bloomston, PM ;

Rosemurgy, AS ;

Giarelli, N ;

Cojita, D ;

Yeatman, TJ ;

Zervos, EE .

AMERICAN JOURNAL OF SURGERY, 2003, 186 (05) :431-436

[23] Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib [J].

Eberhard, DA ;

Johnson, BE ;

Amler, LC ;

Goddard, AD ;

Heldens, SL ;

Herbst, RS ;

Ince, WL ;

Jänne, PA ;

Januario, T ;

Johnson, DH ;

Klein, P ;

Miller, VA ;

Ostland, MA ;

Ramies, DA ;

Sebisanovic, D ;

Stinson, JA ;

Zhang, YR ;

Seshagiri, S ;

Hillan, KJ .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (25) :5900-5909

[24]

FOROUZESH B, 2002, J CLIN ONCOL, V20, P137

[25] Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer [J].

Fukuoka, M ;

Yano, S ;

Giaccone, G ;

Tamura, T ;

Nakagawa, K ;

Douillard, JY ;

Nishiwaki, Y ;

Vansteenkiste, J ;

Kudoh, S ;

Rischin, D ;

Eek, R ;

Horai, T ;

Noda, K ;

Takata, I ;

Smit, E ;

Averbuch, S ;

Macleod, A ;

Feyereislova, A ;

Dong, RP ;

Baselga, J .

JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (12) :2237-2246

[26]

Gatzemeier U, 2004, J CLIN ONCOL, V22, p619S

[27]

GATZEMEIER U, 2005, J CLIN ONCOL, V23

[28]

GEORGE CM, 2003, J CLIN ONCOL, V21, P229

[29]

GIACCONE G, 2005, J CLIN ONCOL, V23

[30] Efficacy and safety of erlotinib HCl, an epidermal growth factor receptor (HER1/EGFR) tyrosine kinase inhibitor, in patients with advanced ovarian carcinoma: results from a phase II multicenter study [J].

Gordon, AN ;

Finkler, N ;

Edwards, RP ;

Garcia, AA ;

Crozier, M ;

Irwin, DH ;

Barrett, E .

INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2005, 15 (05) :785-792

← 1 2 3 4 5 6 7 8 9 10 →